ObsEva News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

07.11.19	ObsEva Announces Third Quarter 2019 Financial Results (GlobeNewswire)
07.11.19	Obseva Announces That Nolasiban Implant 4 Study Did Not Meet Primary Endpoint (GlobeNewswire)
06.11.19	ObsEva SA to Hold Conference Call to Discuss IMPLANT 4 Trial Results and Third Quarter 2019 Financial and Business Update on November 7, 2019 (GlobeNewswire)
06.11.19	ObsEva SA to Participate in Upcoming Investor Conferences (GlobeNewswire)
04.11.19	ObsEva SA to Hold Third Quarter 2019 Financial Results and Business Update Call on November 11, 2019 (GlobeNewswire)
31.10.19	ObsEva Announces Clearance to Initiate Pivotal US Phase 3 Clinical Trial (IMPLANT 3) of Nolasiban in Women Undergoing Embryo Transfer Following IVF (GlobeNewswire)
11.10.19	ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy (GlobeNewswire)
09.10.19	ObsEva SA to Present New Clinical Data on its Lead Compounds Nolasiban and Linzagolix at the 75th Annual ASRM Meeting in Philadelphia, PA (GlobeNewswire)
27.09.19	ObsEva SA to Participate in Cantor Global Healthcare Conference October 2-4, 2019 (GlobeNewswire)
03.09.19	ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate Following Embryo Transfer in IVF (GlobeNewswire)
30.08.19	ObsEva SA to Participate in Upcoming Investor Conferences (GlobeNewswire)
09.08.19	ObsEva SA to Participate in Wedbush PacGrow Healthcare Conference August 13-14, 2019 (GlobeNewswire)
07.08.19	ObsEva SA Announces $75 Million Credit Facility with Oxford Finance LLC (GlobeNewswire)
07.08.19	ObsEva Reports Second Quarter 2019 Financial Results (GlobeNewswire)
05.08.19	ObsEva SA to Hold Second Quarter 2019 Financial Results and Business Update Call on August 7, 2019 (GlobeNewswire)
26.07.19	ObsEva SA Reports Positive Feedback from Independent Data Monitoring Committee for PROLONG Part B with OBE022 (GlobeNewswire)
18.07.19	ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares (GlobeNewswire)
17.07.19	ObsEva Hosts KOL Meeting on IVF Trends, Unmet Need and Market Potential of Nolasiban (GlobeNewswire)
12.07.19	ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) July 17, 2019 in New York City (GlobeNewswire)
08.07.19	ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 1 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids (GlobeNewswire)
01.07.19	ObsEva appoints industry expert as Chief Medical Officer to further advance its Phase 3 clinical programs (GlobeNewswire)
21.06.19	ObsEva SA to Present Nolasiban and Linzagolix Clinical Data at the ESHRE Annual Meeting June 23-26 in Vienna (GlobeNewswire)
19.06.19	ObsEva Progressing Toward U.S. Phase 3 Trial for Nolasiban in IVF Following Recent FDA Meeting (GlobeNewswire)
04.06.19	ObsEva SA Announces Completion of Patient Recruitment in IMPLANT 4 Phase 3 Clinical Trial of Nolasiban for Improving IVF Outcomes (GlobeNewswire)
16.05.19	ObsEva SA to Participate in Upcoming Investor Conferences (GlobeNewswire)
09.05.19	ObsEva Reports First Quarter 2019 Financial Results (GlobeNewswire)
09.05.19	ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S., Canada and Europe (GlobeNewswire)
08.05.19	ObsEva SA Announces that ObsEva’s Shareholders Approved all Board Proposals at its 2019 Annual General Meeting held on May 8, 2019 (GlobeNewswire)
03.05.19	ObsEva SA Reports Consistent Long-Term Findings from Phase 2b EDELWEISS trial of Linzagolix for Endometriosis-Associated Pain (GlobeNewswire)
01.05.19	ObsEva SA to Hold First Quarter 2019 Financial Results and Business Update Call on May 9, 2019 (GlobeNewswire)
29.04.19	ObsEva SA Reports Further Infant Follow-up Data from IMPLANT2 Trial Echoing Favorable Safety Profile of Nolasiban in IVF (GlobeNewswire)
01.04.19	ObsEva SA to Participate in Upcoming Investor Conferences (GlobeNewswire)
29.03.19	Publication of ObsEva SA Invitation to 2019 Annual General Meeting of Shareholders (GlobeNewswire)
13.03.19	ObsEva SA to Present OBE022 Clinical Data for Treatment of Pre-term labor (PTL) at the SRI 66th Annual Scientific Meeting, March 12 -16, 2019 (GlobeNewswire)
05.03.19	ObsEva Reports Fourth Quarter and Full Year 2018 Financial Results, Provides Business Update (GlobeNewswire)
27.02.19	ObsEva SA to Hold Fourth Quarter and Full Year 2018 Financial Results and Business Update Call on March 5, 2019 (GlobeNewswire)
22.02.19	ObsEva SA to Participate in Upcoming Investor Conferences (GlobeNewswire)
23.01.19	ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG Trial (GlobeNewswire)
02.01.19	ObsEva SA to Participate in JP Morgan Healthcare Conference January 7-10, 2019 (GlobeNewswire)
21.12.18	ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 2 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids (GlobeNewswire)
07.12.18	ObsEva R&D Day Showcases Multiple Women’s Health Programs and Outlines Plans for Transition to Commercial Operations (GlobeNewswire)
06.12.18	ObsEva SA to Participate in BMO Healthcare Conference December 12, 2018 (GlobeNewswire)
29.11.18	ObsEva SA to Host R&D Investor Day December 7, 2018 (GlobeNewswire)
28.11.18	ObsEva SA Announces Initiation of Phase 3 IMPLANT 4 Trial of Nolasiban in Europe, Canada and Russia for Improving IVF Outcomes (GlobeNewswire)
08.11.18	ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update (GlobeNewswire)
07.11.18	ObsEva SA to Participate in November Investor Conferences (GlobeNewswire)
31.10.18	ObsEva SA to Hold Third Quarter 2018 Financial Results and Business Update Call on November 8, 2018 (GlobeNewswire)
09.10.18	ObsEva SA Presents Clinical Data from Phase III IMPLANT 2 Trial of Nolasiban in IVF at the American Society of Reproductive Medicine (ASRM) Annual Meeting (GlobeNewswire)
05.10.18	ObsEva To Present Phase 3 IMPLANT 2 Clinical Trial Results Of Nolasiban In IVF (RTTNews)
05.10.18	ObsEva SA Announces Phase 3 IMPLANT 2 Clinical Trial Results of Nolasiban in IVF to be Presented at Annual ASRM Meeting Tuesday October 9, 2018 (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	82.24	2.93 %	K V
Part Grp Hldg	1’404.00	1.67 %	K V
CieFinRichemont	170.10	1.10 %	K V
Kuehne+Nagel Int	206.60	0.98 %	K V
Holcim	89.82	0.92 %	K V
ABB	53.58	0.04 %	K V
Givaudan	3’941.00	-0.10 %	K V
Geberit	498.50	-0.46 %	K V
Alcon	80.46	-0.54 %	K V
Sonova Hldg	314.80	-1.16 %	K V

mehr

27.09.24		Gewinne in Zürich: SPI präsentiert sich zum Ende des Freitagshandels fester
27.09.24		SPI aktuell: SPI klettert
24.09.24		Gewinne in Zürich: SPI beendet den Dienstagshandel mit Gewinnen
23.09.24		Gewinne in Zürich: SPI bewegt schlussendlich im Plus
23.09.24		Gute Stimmung in Zürich: SPI notiert im Plus
21.08.24		Anleger in Zürich halten sich zurück: SPI beendet die Sitzung im Minus
15.08.24		Börse Zürich in Grün: SPI legt zum Handelsende zu
15.08.24		Börse Zürich in Grün: SPI in der Gewinnzone

27.09.24

Gewinne in Zürich: SPI präsentiert sich zum Ende des Freitagshandels fester

27.09.24

SPI aktuell: SPI klettert

24.09.24

Gewinne in Zürich: SPI beendet den Dienstagshandel mit Gewinnen

23.09.24

Gewinne in Zürich: SPI bewegt schlussendlich im Plus

23.09.24

Gute Stimmung in Zürich: SPI notiert im Plus

21.08.24

Anleger in Zürich halten sich zurück: SPI beendet die Sitzung im Minus